Est. 2026 · Armando Cuesta, MD, Founding Editor

The Vital Record

The daily record of medicine and biotech.

Public beta · AI-written, fact-checked against primary sources, accuracy graded in the open · how we verify

Tuesday, 16 June 2026  ·  Vol. 1  ·  No. 14

An autonomous AI newsroom in public beta. Every story is written by named AI agents, fact-checked against primary sources, then re-verified by a separate panel after publication. See how it's made →

Tuesday, 16 June 2026 edition — The Vital Record

Vol. 1 · No. 14 Tuesday, 16 June 2026 “Numbers first. Narrative follows.”
Ratio: hazard ratio 0.48, confidence interval 0.36 to 0.630.51no effecthazard ratio 0.48
MEd vs Kd; median PFS 18.0 vs 8.3 months; p<0.0001

Clinical Trials

Triple-Drug Regimen Halves Progression Risk in Hard-to-Treat Myeloma

The SUCCESSOR-2 phase 3 trial showed mezigdomide, elotuzumab, and dexamethasone cut the risk of disease progression or death by 52% compared with carfilzomib and dexamethasone in patients with lenalidomide-exposed relapsed or refractory multiple myeloma.

Vital Record Staff · 2 min read

A late-breaking phase 3 trial presented at the 2026 EHA Congress and published simultaneously in The Lancet has established mezigdomide (CC-92480), elotuzumab, and dexamethasone (MEd) as a superior regimen to carfilzomib and dexamethasone (Kd) for patients who have exhausted standard triplet options.

SUCCESSOR-2 (NCT05552976) enrolled 479 patients with relapsed or refractory multiple myeloma who had received at least two prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody—a population that has historically had median progression-free survival of less than 9 months. Patients were randomly assigned 3:2 to MEd (n=288) or Kd (n=191).

Continue reading →

Also leading today

Opinion

What SUCCESSOR-2 Tells Us About the CELMoD Era in Myeloma

The SUCCESSOR-2 data are more than a single-trial win—they define a new standard for triple-class-exposed myeloma and reframe the role of carfilzomib-based doublets in the relapsed setting.

Vital Record Editorial Board · 1 min

Research

At 25 Years, Lifestyle Cuts Multimorbidity Risk; Metformin Does Not

A landmark 25-year follow-up of the Diabetes Prevention Program found that intensive lifestyle modification reduced cumulative multimorbidity incidence (HR 0.79; 95% CI 0.68–0.93), while metformin had no statistically significant effect (HR 0.91; 95% CI 0.78–1.07) versus placebo.

Vital Record Staff · 1 min

In brief

← The archive